CINECA IRIS Institutional Research Information System

DI NICOLANTONIO, Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.605
AS - Asia 17.543
EU - Europa 17.005
SA - Sud America 1.740
Continente sconosciuto - Info sul continente non disponibili 1.139
OC - Oceania 386
AF - Africa 273
Totale 61.691
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.399
CN - Cina 7.855
IT - Italia 5.686
SG - Singapore 3.096
DE - Germania 1.642
GB - Regno Unito 1.563
FR - Francia 1.468
JP - Giappone 1.413
BR - Brasile 1.082
VN - Vietnam 866
CA - Canada 781
IN - India 754
KR - Corea 744
HK - Hong Kong 739
ES - Italia 717
IE - Irlanda 702
FI - Finlandia 687
NL - Olanda 655
RU - Federazione Russa 654
SE - Svezia 546
PL - Polonia 495
TW - Taiwan 375
TR - Turchia 317
AU - Australia 315
CH - Svizzera 283
AT - Austria 276
BE - Belgio 276
UA - Ucraina 276
MX - Messico 273
BD - Bangladesh 233
ID - Indonesia 231
AR - Argentina 194
GR - Grecia 177
DK - Danimarca 168
CO - Colombia 132
IL - Israele 124
RO - Romania 124
TH - Thailandia 108
PE - Perù 103
PT - Portogallo 100
CZ - Repubblica Ceca 98
NO - Norvegia 86
HU - Ungheria 82
CL - Cile 80
EC - Ecuador 79
IQ - Iraq 72
IR - Iran 72
NZ - Nuova Zelanda 69
JO - Giordania 63
ZA - Sudafrica 58
SA - Arabia Saudita 57
PK - Pakistan 53
MY - Malesia 45
AM - Armenia 40
HR - Croazia 37
JM - Giamaica 36
PH - Filippine 34
EG - Egitto 32
SN - Senegal 32
UZ - Uzbekistan 32
MA - Marocco 28
MO - Macao, regione amministrativa speciale della Cina 28
TN - Tunisia 27
LB - Libano 26
BY - Bielorussia 24
KZ - Kazakistan 23
VE - Venezuela 23
BA - Bosnia-Erzegovina 22
DZ - Algeria 22
PR - Porto Rico 22
AE - Emirati Arabi Uniti 21
NG - Nigeria 21
LT - Lituania 19
CR - Costa Rica 18
NI - Nicaragua 18
SK - Slovacchia (Repubblica Slovacca) 18
EU - Europa 17
LU - Lussemburgo 17
RS - Serbia 17
SI - Slovenia 17
UY - Uruguay 16
CY - Cipro 15
LV - Lettonia 15
PS - Palestinian Territory 15
AL - Albania 14
AZ - Azerbaigian 14
BG - Bulgaria 14
GY - Guiana 12
HN - Honduras 11
KW - Kuwait 11
NP - Nepal 11
PY - Paraguay 10
SY - Repubblica araba siriana 10
AP - ???statistics.table.value.countryCode.AP??? 9
BO - Bolivia 9
DO - Repubblica Dominicana 9
ET - Etiopia 9
GH - Ghana 9
QA - Qatar 9
TT - Trinidad e Tobago 9
Totale 60.445
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.555
Singapore 1.780
Beijing 1.594
Ashburn 1.352
Chandler 942
Shanghai 862
Houston 840
Fairfield 818
San Jose 744
Milan 662
Dublin 651
Redwood City 629
Santa Clara 606
Guangzhou 539
Torino 539
Hangzhou 470
Seattle 456
Woodbridge 454
Turin 452
Wilmington 438
Tokyo 426
Cambridge 405
New York 400
Dearborn 376
Los Angeles 364
Hong Kong 310
Rome 303
Nanjing 281
The Dalles 278
Villeurbanne 236
Boston 233
Seoul 233
Ho Chi Minh City 228
Warsaw 227
Pisa 226
Helsinki 222
Munich 217
Columbus 201
Buffalo 194
Hanoi 183
Boardman 181
Jacksonville 180
Paris 180
Nyköping 179
Taipei 177
Barcelona 173
Wuhan 172
London 171
Princeton 171
Lauterbourg 166
Dallas 165
Vienna 165
Medford 159
Toronto 155
Hefei 152
Chengdu 147
Lappeenranta 147
Chicago 144
Jakarta 137
Amsterdam 133
Shenzhen 125
San Diego 119
Phoenix 116
Naples 115
Berlin 114
São Paulo 111
Bengaluru 108
Brussels 106
Fremont 104
Dong Ket 103
Frankfurt am Main 102
Tianjin 102
Changsha 101
Shenyang 101
Council Bluffs 100
Turku 96
Bologna 93
Montreal 87
Zhengzhou 87
San Francisco 86
Ottawa 85
Zurich 83
Atlanta 82
Chongqing 82
Istanbul 82
Madrid 81
Washington 81
Chennai 77
Philadelphia 76
Duncan 75
Sydney 74
Lima 73
Central District 72
Melbourne 72
Central 71
Jinan 71
Genoa 70
Nuremberg 70
Florence 69
Mumbai 66
Totale 29.768
Salva come PNG Salva come JPEG
Nome #
High-dose Vitamin C enhances cancer immunotherapy 5.378
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR 5.316
Adaptive mutability of colorectal cancers in response to targeted therapies 2.634
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 2.592
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth 2.450
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 1.614
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.344
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model 1.323
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer 1.217
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 1.004
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer 828
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor 797
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer 774
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer 756
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer 755
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology 713
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. 664
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients 659
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. 652
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer 644
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets 638
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 565
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase 552
Costruzione di linee cellulari isogeniche per mutazioni associate al cancro e loro applicazione per approcci di farmacogenomica 520
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients 496
BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer 484
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer 456
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 454
MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients 448
BRAF V600E is a determinant of sensitivity to proteasome inhibitors. 433
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer 390
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 390
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 373
European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission 355
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin 343
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. 338
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers 318
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 318
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung 316
Evolving neoantigen profiles in colorectal cancers with DNA repair defects 312
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs 311
Exploiting DNA repair defects in colorectal cancer 305
TGF-α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. 304
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 304
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer 301
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor 281
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies 278
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 274
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 273
Small nucleolar RNAs determine resistance to doxorubicin in human osteosarcoma 267
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition 263
Acquired resistance to EGFR-targeted therapies in colorectal cancer. 261
Liquid biopsy: monitoring cancer-genetics in the blood 258
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. 254
Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti– Epidermal Growth Factor Receptor Antibody Therapies 250
The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination 238
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. 236
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer 235
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers 228
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia 227
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 224
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility 223
ISOGENIC HUMAN CELL LINES COMPRISING MUTATED CANCER ALLELES AND PROCESS USING THE CELL LINES 215
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 215
Kras mutations and resistance to anti-egfr treatment 213
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 206
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies 205
Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy 201
Abstract 1163: Microenvironment targets in KRAS-mutated metastatic colorectal cancer 197
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 193
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer 191
Knock-in of oncogenic mutations in human somatic cells as a tool to identify genoselective compounds 188
Evaluation of the preclinical efficacy of lurbinectedin in malignant pleural mesothelioma 188
Anti-EGFR Antibody Therapy Based on an Increased Copy Number of the EGFR Gene in Tumor Tissues 187
Mouse models of Kras mutant colorectal cancer: valuable GEMMs for drug testing? 187
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer 185
BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer 173
Unveiling of BRAF V600E Mutant Cells Sensitivity to Proteasome Inhibitors Using an Isogenic Cell Based Screening 173
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses 172
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer 172
Acquired Resistance to Anti EGFR Therapy in Colorectal Cancer and Paracrine Protection by KRAS Mutated Cells 170
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. 170
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours 169
Fibroblast Growth Factor Receptor (FGFR)3 sustains acquired resistance to trastuzumab in gastric cancer patients 168
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer 168
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer 168
Precision oncology for KRASG12C-mutant colorectal cancer 167
Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein 165
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance 162
Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer 161
Cancer cell adaptation to chemotherapy 160
Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity 159
Circulating methylated DNA to monitor the dynamics of RAS mutation clearance in plasma from metastatic colorectal cancer patients 157
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. 156
EMERGENCE OF KRAS MUTATIONS AND ACQUIRED RESISTANCE TO ANTI EGFR THERAPY IN COLORECTAL CANCER 155
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer 155
DNA demethylation triggers cell free DNA release in colorectal cancer cells 153
Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells 151
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study 150
Climbing RAS, the Everest of Oncogenes. 149
Totale 53.082
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.894
article - articoli 0
book - libri 0
conference - conferenze 12.998
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 145.892
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226.529 0 822 767 942 470 399 521 464 530 366 680 568
2022/20236.609 484 435 407 512 443 875 512 483 1.146 348 528 436
2023/20245.896 532 508 481 474 543 532 396 506 183 614 549 578
2024/20258.806 414 517 696 825 1.233 745 571 643 882 700 677 903
2025/202611.958 1.130 589 695 1.316 1.158 715 1.530 557 1.056 816 805 1.591
2026/20271.361 621 740 0 0 0 0 0 0 0 0 0 0
Totale 61.691